cDNA to these cells in a site-specifi c manner. Unwanted sequences were then precisely deleted with Cre resolvase. Pluripotency of the iPS cells before and after gene addition was verifi ed. Ability of the modifi ed iPS cells to differentiate into myogenic precursors was demonstrated by microscopy, immunohistochemistry, qRT-PCR, and FACS analysis. These data highlight the utility of Bxb1 integrase for precise site-specifi c integration and the feasibility of creating dystrophin-positive iPS-derived myogenic cells for personalized cell therapy approaches in muscle.
Engraftment of Mesenchymal Stromal Cells That Can Differentiate To Form Myogenic Cells Is Enhanced by Expressing IL-10 in Dog with Duchenne Muscular Dystrophy
Yuko N. Kasahara, 1 Hiromi H. Kinoh, 1 Tomoko Chiyo, 1 Hironori Okada, 1 Takashi Okada, 1 Shin'ichi Takeda. 1 1 Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Background: Duchenne muscular dystrophy (DMD) is an incurable genetic disease with early mortality. Multipotent mesenchymal stromal cells (MSCs) could be a potential therapeutics because of their ability to differentiate to form myogenic cells in situ with immunosuppressive properties. MSCs were also obtained market authorization as the product for treatment of acute graft-vs-host disease in Canada and New Zealand (2012) . Previously, we reported the methods to expand MSCs culture with the myogenic differentiation. In the present study, we established the strategies for effective cell transplantation, to develop a novel approach for the treatment of DMD. Methods: Canine CD271-positive (+) MSCs obtained from donor bone marrow cells were enriched and then transduced with MyoD and/or IL-10. Cardiotoxin (CTX) was injected into tibialis anterior (TA) muscles of normal Beagle dog 5 days before MSCs injection. CD271 + MSCs (2x10 6 cells) were injected into the TA muscles of recipient canine X-linked muscular dystrophy in Japan (CXMD J ) without immunosuppression. For intra-arterial injection, CD271 + MSCs (5x10 6 cells) were administered into the femoral artery with papaverin hydrochloride. The transplanted muscles were biopsied and analyzed histologically. IL-10 and luciferase-transduced rat MSCs (5x10 6 cells) were also injected into lower legs of NOD/ SCID mice. After the injection, in vivo fl uorescence imaging was performed with an IVIS-Spectrum to assess cell survival, homing and engraftment effi ciency in transplanted mice. Results: MyoD transduction of MSCs caused myogenic differentiation in vitro and in vivo. Canine CD271 + MSCs in the myogenic cell lineage were transplanted into CXMD J and formed clusters of musclelike tissue at 12 weeks after the intra-muscular injection without immunosuppression. The engraftment of CD271 + MSCs was also found at the site of CTX-injured muscle after the intra-arterial injection. We also investigated the effects of MSCs expressing IL-10 on the engraftment of MSCs into the muscle. IL-10 expressing MSCs showed signifi cant increase of engraftment (9-fold) when compared with normal MSCs at 4 weeks after transplantation and survived for more than 8 weeks after the transplantation in NOD/SCID mouse. Similar effects with 2-fold increase were also detected when IL-10transduced CD271 + MSCs were injected into dog. Conclusion: MyoDtransduced CD271 + MSCs enabled more effi cient realization of MSCs transplantation by the intra-muscular as well as intra-arterial injection. Furthermore, regulation of infl ammation as well as apoptosis might be involved in the enhanced engraftment of MSCs. This strategy of MSCs propagation and treatment would be promising for the future DMD cell therapy. Myoblast transplantation has potential as a gene delivery and cellular therapy strategy for musculoskeletal disorders. Injection of wild-type or corrected autologous myoblasts has been proposed as a method to introduce functional dystrophin to treat Duchenne muscular dystrophy. Although transplanted myoblasts fuse with host muscle fi bers immediately surrounding the injection site, effi cient engraftment throughout the muscle has been diffi cult to achieve due to the diminished proliferative capacity of cells post-implantation. Terminal differentiation of the implanted myoblasts soon after injection may contribute to this inability to suffi ciently populate the muscle. Cell cycle exit and cessation of proliferation, a key step in the terminal differentiation of myoblasts, is orchestrated by cyclindependent kinase inhibitor (CKI) p21, retinoblastoma protein, and INK4 CKIs. p21 is upregulated early in myogenic differentiation, and reduced expression of p21 in terminally differentiated myotubes has been shown to cause reentry into S phase of the cell cycle. We hypothesized that reduced expression of p21 in myoblasts would inhibit differentiation and increase growth capacity. CKI p21 is an ideal target for silencing because of a reduced risk of oncogenic side effects compared to knockdown of tumor suppressors Rb and INK4. Using a lentiviral vector expressing short hairpin RNA (shRNA) against p21, we achieved over 85% knockdown of p21 expression in C2C12s, a mouse myoblast cell line, and primary myoblasts. In differentiation conditions, myoblast fusion into myotubes was dramatically reduced in p21 shRNA-expressing cells relative to non-treated and non-specifi c shRNA-treated controls. However, myogenesis was not completely inhibited: p21 shRNA-treated myoblasts showed similar upregulation of myogenic markers myogenin, troponin T, desmin, and creatine kinase as control cells after induction of differentiation. This suggests that silencing p21 does not disrupt commitment to the myoblast lineage. Additionally, in a mixed population culture of p21 shRNA lentivirus-transduced and non-transduced myoblasts, the transduced cells are enriched over multiple passages, suggesting higher growth rates for p21-shRNA expressing myoblasts. In low serum culture, a signifi cantly higher percentage of p21 shRNA-treated myoblasts remain active in the cell cycle by progressing to S phase. These fi ndings indicate that modulating p21 expression may be an effective means of improving myoblast transplantation by delaying fusion with the host muscle and imparting a proliferative advantage to donor cells. Ongoing myoblast implantation studies will determine how modifying myoblast growth and fusion capacity affects engraftment effi ciency. Future work with an inducible p21 shRNA expression system will determine if restoring p21 will result in the recovery of the myoblast differentiation and cell fusion. Reversible silencing of p21 expression to encourage cell growth and slow differentiation may increase donor cell engraftment in the host, an important factor in the success of cell-based gene delivery for muscular dystrophy.
Modulating Cell Cycle Inhibitor Expression To Enhance Skeletal Myoblast Engraftment

Human Muscle Derived Stem Cells Exhibit Bone Regeneration Capacity Similar to Bone Marrow Mesenchymal Stem Cells When Genetically Modifi ed To Express BMP2 Both In Vitro and In Vivo
Xueqin Gao, 1 Arvydas Usas, 1 Ying Tang, 1 Aiping Lu, 1 Jian Tan, 1 Johannes Schneppendahl, 1 Nick Oyster, 1 Bing Wang, 1 Rocky Tuan, 1 Johnny Huard. 1 1 Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA.
Introduction: Human muscle-derived stem cells (hMDSCs) isolated by a modifi ed preplate technique possess multi-lineage differentiation capacity in vitro and form bone in vivo when transduced with BMP2. In order to test whether hMDSCs are as effective as human bone marrow mesenchymal stem cells (hBMMSCs) for bone regeneration, we compared hMDSCs and hBMMSCs for their in vitro osteogenic differentiation and in vivo bone regeneration capacity in a mouse calvarial defect model. Methods: (1) 4 populations of hMDSCs and hBMMSCs were isolated using established protocols (2) Both hMDSCs and hBMMSCs were transduced with lenti-BMP2 virus in the presence of polybrene (8μg/ml) for 16 hrs. After transduction, all the cells were selected with 10μg/ml blasticidin for 24hrs and further expanded. BMP2 secretion levels were measured using ELISA. (3) Gene expression comparisons of the hMDSCs and hBMMSCs were performed using semi-quantitative RT-PCR. Alkaline phosphatase (ALP) staining was also performed. (4) In vitro osteogenesis capacities were compared using pellet culture. (5) In vivo bone regeneration capacities of transduced and non-transduced hMDSC and hBMMSC were tested using a critical size calvarial bone defect model. Fibrin sealant was used as a scaffold. (6) MicroCT scans were performed at days 1, 14, 28 and 42 post-implantation. (7) Histology: Herovici's staining was used to identify type I collagen and HE staining was also peerformed. Results: (1) The BMP2 secretion levels of the 4 populations of hMDSCs at the time of implantation were: 2.8, 1.2, 0.48, 0.3 ng/million/24hrs respectively; the BMP2 secretion levels of the 4 populations of hBMMSCs were: 29.9, 12.7, 14.1, 14.1 ng/million/24hrs respectively. (2) hMDSCs and hBMMSCs exhibited similar expression levels of BMPR2,BMPR1b, COX-2 and SOX-9. COX-2 expression was increased in both transduced cell groups. ALP was expressed in a small percentage of the non-transduced cells and was slightly increased after lenti-BMP2 transduction. (3) Both cell populations could undergo osteogenesis in vitro without transduction as shown by microCT and von Kossa staining. Lenti-BMP2 transduction enhanced osteogenesis. (4) Both hMDSCs and hBMMSCs exhibited limited bone regeneration without gene transduction in vivo. (5) hMDSCs demonstrated an equal bone defect repair capacity as the hBMMSCs when transduced with lenti-BMP2 as indicated by microCT in vivo. (6) Histological analysis revealed formation of the main bone matrix-type I collagen in the defect area in both the hMDSC and hBMMSC groups. HE staining revealed bone remodeling of the new bone in both cell groups as shown by the appearance of multinuclear osteoclasts in the bone marrow. Conclusion: Our results indicated that hMDSCs exhibited an equivalent osteogenic capacity as the hBMMSCs in vitro and in vivo. Genetic modifi cation of both the hMDSCs and hBMMSCs with lenti-BMP2 is required for effi cient in vivo bone regeneration. Therefore, hMDSCs could be used as an alternative source of human adult stem cells for bone repair. Duchenne muscular dystrophy (DMD) is a deadly genetic disease characterized by a lack of dystrophin expression and progressive weakening and wasting of the skeletal muscles. Researchers have observed that despite the lack of dystrophin at birth, the histopathological signs of muscle weakness do not become apparent until 4-8 years of age. This happens to coincide with the exhaustion of the muscle progenitor cell (MPC) pool. There are several lines of evidence to support that human DMD progression is a consequence of loss of functional MPCs. The dystrophin defi cient mice (mdx), a mouse model of DMD, have mild skeletal muscle weakness, potent regeneration capacity, and also a greater MPCs reserve. There is another mouse model, known as the dystrophin/utrophin double Knock-Out (dKO, dys -/utro -/-), which is a severe mouse model with a short life span (6-8 weeks) . In this study we focused on the dKO mouse model to determine if rapid progression of muscular dystrophy is associated with MPC exhaustion compared to mdx mice. dKO and mdx muscle cryosections were immunofl uorescently stained for Pax7(satellite cell marker), F4/80 ( macrophage marker) and eMyHC (embryonic myosin heavy chain) by using the M.O.M kit and specifi c antibodies. The results showed that the number of Pax7 + cells and eMyHC+ fi bers from dKO muscle was signifi cantly decreased, but infi ltration of F4/80 + macrophages increased during aging and disease progression compared to mdx mice. Flow cytometry results indicated that the CD34+Sca-1-CD45-cells signifi cantly declined in dKO muscle from new born to 8 weeks old mice. MPCs were also isolated from 6 week old dKO and mdx mice, as previously described via a modifi ed preplate technique. The proliferation behavior of the MPCs isolated from dKO and mdx muscle was examined by using live cell imaging system. The myogenic differentiation capacity of the MPCs was assessed by staining of fast myosin heavy chain (MyHCf). We found that MPCs isolated from dKO mice have a reduced ability to proliferate and differentiate compared to MPCs isolated from mdx mice. Cellular resistance to hydrogen peroxideinduced oxidative stress was also examined and dKO MPCs displayed a reduced resistance to oxidative stress, compared to the mdx MPCs. In addition, single muscle fi bers were isolated from 6 week old dKO mice and mdx mice. The results demonstrated impaired proliferation potential of MPCs from dKO mice up to fi ve days post culturing. In contrast, mdx muscle fi bers were able to release myogenic progenitor cells and form new MyHCf+ myotubes. Taken together, these results suggest that the MPCs from dKO mice have a functional defect and rapid muscle progenitor cell exhaustion is associated with progression of muscular dystrophy which may contribute to the histopathology associated with DMD. These observations suggest that blocking the exhaustion of the MPC pool could be a new approach to improve muscle weakness in DMD patients, despite the continued lack of dystrophin expression.
Rapid Progression of Muscular Dystrophy in Dystrophin/Utrophin -/-Mice Is Associated with Muscle Progenitor Cell Exhaustion
